143 related articles for article (PubMed ID: 12922090)
1. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination.
Hanslik T; Boëlle PY; Schwarzinger M; Carrat F; Freedberg KA; Valleron AJ; Flahault A
Vaccine; 2003 Sep; 21(25-26):3614-22. PubMed ID: 12922090
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of varicella vaccination of healthcare workers.
Chodick G; Ashkenazi S; Livni G; Lerman Y
Vaccine; 2005 Oct; 23(43):5064-72. PubMed ID: 16046036
[TBL] [Abstract][Full Text] [Related]
3. The economic value of childhood varicella vaccination in France and Germany.
Coudeville L; Brunot A; Szucs TD; Dervaux B
Value Health; 2005; 8(3):209-22. PubMed ID: 15877593
[TBL] [Abstract][Full Text] [Related]
4. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles.
Smith WJ; Jackson LA; Watts DH; Koepsell TD
Obstet Gynecol; 1998 Oct; 92(4 Pt 1):535-45. PubMed ID: 9764625
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of vaccination strategies in adults without a history of chickenpox.
Smith KJ; Roberts MS
Am J Med; 2000 Jun; 108(9):723-9. PubMed ID: 10924649
[TBL] [Abstract][Full Text] [Related]
6. Varicella vaccination in Italy : an economic evaluation of different scenarios.
Coudeville L; Brunot A; Giaquinto C; Lucioni C; Dervaux B
Pharmacoeconomics; 2004; 22(13):839-55. PubMed ID: 15329030
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
Ahern S; Browne J; Murphy A; Teljeur C; Ryan M
Vaccine; 2024 May; 42(14):3321-3332. PubMed ID: 38609807
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of a routine varicella vaccination program for US children.
Lieu TA; Cochi SL; Black SB; Halloran ME; Shinefield HR; Holmes SJ; Wharton M; Washington AE
JAMA; 1994 Feb; 271(5):375-81. PubMed ID: 8283587
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of routine childhood varicella vaccination in Germany.
Banz K; Wagenpfeil S; Neiss A; Goertz A; Staginnus U; Vollmar J; Wutzler P
Vaccine; 2003 Mar; 21(11-12):1256-67. PubMed ID: 12559807
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents.
Lieu TA; Finkler LJ; Sorel ME; Black SB; Shinefield HR
Pediatrics; 1995 May; 95(5):632-8. PubMed ID: 7724297
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness and budget impact of universal varicella vaccination in Russia.
Marijam A; Safonova E; Scherbakov M; Shpeer E; Van Oorschot D; Rudakova A; Tatochenko V; Briko N
Hum Vaccin Immunother; 2022 Nov; 18(5):2045152. PubMed ID: 35258445
[TBL] [Abstract][Full Text] [Related]
13. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.
Wutzler P; Neiss A; Banz K; Goertz A; Bisanz H
Med Microbiol Immunol; 2002 Oct; 191(2):89-96. PubMed ID: 12410347
[TBL] [Abstract][Full Text] [Related]
14. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers.
Nettleman MD; Schmid M
Infect Control Hosp Epidemiol; 1997 Jul; 18(7):504-8. PubMed ID: 9247834
[TBL] [Abstract][Full Text] [Related]
15. Varicella serology among school age children with a negative or uncertain history of chickenpox.
Lieu TA; Black SB; Takahashi H; Ray P; Capra AM; Shinefield HR; Adler NE
Pediatr Infect Dis J; 1998 Feb; 17(2):120-5. PubMed ID: 9493807
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of varicella vaccination in Swiss children and adolescents.
Banz K; Iseli A; Aebi C; Brunner M; Schmutz AM; Heininger U
Hum Vaccin; 2009 Dec; 5(12):847-57. PubMed ID: 19829048
[TBL] [Abstract][Full Text] [Related]
17. Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland.
Heininger U; Pillsbury M; Samant S; Lienert F; Guggisberg P; Gani R; O'Brien E; Pawaskar M
Pediatr Infect Dis J; 2021 Jun; 40(6):e217-e221. PubMed ID: 33872276
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule.
Scuffham P; Devlin N; Eberhart-Phillips J; Wilson-Salt R
Soc Sci Med; 1999 Sep; 49(6):763-79. PubMed ID: 10459888
[TBL] [Abstract][Full Text] [Related]
19. Varicella vaccination in England and Wales: cost-utility analysis.
Brisson M; Edmunds WJ
Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of varicella vaccination in Canada.
Brisson M; Edmunds WJ
Vaccine; 2002 Jan; 20(7-8):1113-25. PubMed ID: 11803072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
